Concepedia

Xiaoli S. Glasgow

XS

Statistics

Publications

4

Citations

106

H-Index

4

Active since

2016

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Xiaoli S. Glasgow is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in diabetes, pharmacotherapy, and medicine.

Top concepts

Publications per year

2016–2018

4

Publications

4

Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects

Rajesh Krishna, Carol Addy, Daniel Tatosian et al. · The Journal of Clinical Pharmacology · 2016 · 33 citations · Full text

Effect of tildrakizumab (MK‐3222), a high affinity, selective anti‐IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis

Sauzanne Khalilieh, Azher Hussain, Diana Montgomery et al. · British Journal of Clinical Pharmacology · 2018 · 33 citations · Full text

Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus

Carol Addy, Daniel Tatosian, Xiaoli S. Glasgow et al. · Clinical Therapeutics · 2016 · 27 citations

, , +7

A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once‐Weekly DPP‐4 Inhibitor, Does Not Prolong the QTc Interval

Daniel Tatosian, Nadia Cardillo Marricco, Xiaoli S. Glasgow et al. · Clinical Pharmacology in Drug Development · 2016 · 13 citations

1–4 of 4